Boehringer Ingelheim (BI) has invested EUR 52 million ($55 million) in a new building that recently opened at the Research Institute of Molecular Pathology (IMP) in Vienna earlier this month. The new building will house 200 scientists from nearly 40 countries.

The new building is located in the Vienna Biocenter, the life science cluster of Vienna, and aims to strengthen Austria and Europe in global research and development. The IMP is focused on studying basic molecular and cellular processes to better understand complex biological processes. BI is the main sponsor of IMP, to which it annually contributes around EUR 20 million ($21 million) without taking influence on projects or research areas chosen by the IMP, according to information from BI. 

Source: Boehringer Ingelheim